Bitdeer Announces Third Quarter 2025 Earnings Conference Call for November 10, 2025

(NASDAQ:BTDR), SINGAPORE, Oct. 30, 2025 (GLOBE NEWSWIRE) — Bitdeer Technologies Group (NASDAQ: BTDR) (“Bitdeer” or the “Company”), a world-leading technology company for Bitcoin mining and AI cloud, today announced that it has scheduled its third quarter 2025 earnings conference call and webcast for Monday, November 10, 2025 at 8:00 AM EST. During the call, Bitdeer […]

Wellchange Holdings Company Receives 180-Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Requirement

(NASDAQ:WCT), Hong Kong, Oct. 30, 2025 (GLOBE NEWSWIRE) — Wellchange Holdings Company (NASDAQ: WCT) (“Wellchange” or the “Company”), today announced that it has received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) granting the Company an additional 180-calendar-day compliance period, or until April 27, 2026, to regain compliance

Premier American Uranium Announces Preliminary Economic Assessment and Mineral Resource Update for the Cebolleta Uranium Project, Outlining Project Economics and Framework for Enhancement

(TSX-V:PUR),(OTC US:PAUIF),(Other OTC:PAUIF), TORONTO, Oct. 30, 2025 (GLOBE NEWSWIRE) — Premier American Uranium Inc. (“PUR” or “Premier American Uranium” or the “Company”) (TSXV: PUR, OTCQB: PAUIF) is pleased to announce the results of its Preliminary Economic Assessment (“PEA“) for the Cebolleta Uranium Project (“Cebolleta” or the “Project“) in New Mexico. The PEA highlights the potential

Aldebaran PEA for the Altar Project Reports 48 Year Mine Life, After Tax NPV (8%) of US$2 Billion, and 20.5% IRR

(TSX-V:ALDE),(TSX-V:ALDE.V),(OTC US:ADBRF),(Other OTC:ADBRF), VANCOUVER, British Columbia, Oct. 30, 2025 (GLOBE NEWSWIRE) — Aldebaran Resources Inc. (“Aldebaran” or the “Company“) (TSX-V: ALDE, OTCQX: ADBRF) is pleased to announce the results of a Preliminary Economic Assessment (“PEA”), prepared in accordance with National Instrument 43-101 standards, for the Altar copper-gold project located in San Juan, Argentina. The base

AmpliTech Group Announces Unit Rights Offering

(NASDAQ:AMPG),(NASDAQ:AMPGW), HAUPPAUGE, N.Y., Oct. 30, 2025 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (Nasdaq: AMPG, AMPGW) (the “Company” or “AmpliTech”), a leading designer and manufacturer of advanced signal-processing components for satellite, 5G/6G networks, and quantum systems, today announced that it intends to offer to its shareholders and certain warrantholders a dividend in the form of a

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

(NASDAQ:PHAT), Over 790,000 total VOQUEZNA(R) prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarter Full-year 2025 revenue guidance updated to $170-$175 million; company expects to achieve operating profitability in 2026 Management to host

Aduro Clean Technologies Provides Update on NGP Pilot Plant Commissioning

(CNSX:ACT.CN),(OTC US:ACTHF),(Other OTC:ACTHF),(Boerse Frankfurt – Freiverkehr:9D5),(NASDAQ:ADUR), LONDON, Ontario, Oct. 30, 2025 (GLOBE NEWSWIRE) — Aduro Clean Technologies Inc. (“Aduro” or the “Company“) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st

Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors

(NasdaqGM:RNAC), FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that Carsten Brunn, Ph.D., was named as Chairman of the Board of Directors, effective October 29, 2025. Dr. Brunn, who currently serves as the Company's President and

Gain Therapeutics to Present at Neuroscience 2025

(NasdaqGM:GANX), BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the Society for Neuroscience annual meeting, Neuroscience 2025, being held November 15th-19th in

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

(NASDAQ:IBIO), Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation New non-human primate data projects a human half-life of up to 100 days, potentially enabling treatment with only twice-yearly dosing Extended half-life data and differentiated mechanism of action reinforce

Scroll to Top